Altimmune’s pemvidutide achieved a statistically significant reduction in heavy drinking days compared to a placebo in a Phase 2 trial. This peptide drug, which is designed to activate the GLP-1 and glucagon receptors, is also on track to begin a pivotal test in the fatty liver disease MASH.
The post Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol-Use Disorder Trial appeared first on MedCity News.
